Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Taisho Makes Tokuhon Wholly Owned Subsidiary; Expanding Business in Topical, Adhesive Agents
July 4, 2012
- Over 60% of Meiji Seika Pharma’s Generics Have Top 3 Market Share: GM Umeki
July 3, 2012
- Nippon Kayaku in Final Preparatory Stage for NK105 PIII Trials: Managing Director Suzuki
July 3, 2012
- Japan’s 5th DPP-4 Inhibitor Tenelia Approved: MTPC
July 3, 2012
- Otsuka, Kyowa Kirin Announce Strategic Alliance in Fields of Diabetes, Oncology
July 2, 2012
- Astellas Receives Approval for Prostate Cancer Treatment Gonax
July 2, 2012
- Toyama Chemical, Eisai Receive Approval for Anti-Rheumatic Treatment, to Market under 2 Brands
July 2, 2012
- Takeda Initiates International PIII Trial of Velcade Successor
July 2, 2012
- Mirabegron Approved in the US: Astellas
July 2, 2012
- Anti-Obesity Agent Belviq Approved in US, to Be Launched in Jan. 2013: Eisai
July 2, 2012
- Merck Serono No. 1 in Infertility Treatment Market through Ninkatsu Image Strategy
July 2, 2012
- M3, Mediscience, MIC Medical Consider Capital, Operational Alliance to Establish 650 CRAs Structure
June 29, 2012
- Teva Pharma to Streamline Overlapping Products in 3 years: President Shimada
June 29, 2012
- Bayer Yakuhin to Transfer 3 Established Products to FFP
June 29, 2012
- NDA Filed for Gout Treatment Topiroxostat: Fuji Yakuhin, Sanwa Kagaku
June 29, 2012
- FDA Accepts NDA for Ospemifene for VVA: Shionogi
June 29, 2012
- AnGes MG Obtains Exclusive Rights for Vaccine for Precancerous Condition of the Cervix in China
June 28, 2012
- Takeda Ranked No. 1 in Medical Category for 5th Year in a Row: Popularity Rankings for Career Change
June 28, 2012
- DSP Launches Myslee Generic on June 28
June 28, 2012
- Eisai to Make Full-Scale Entry into Russian Market; Antiepileptic Agent Obtains Approval
June 28, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…